Bionano Genomics
BNGO

$0.63

3.24%

Market Cap: 50.7M

About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Employees: 344

Industrials Laboratory Analytical Instruments

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,208% more call options, than puts

Call options by funds: $471K | Put options by funds: $36K

6.93% less ownership

Funds ownership: 15.9% [Q4 2023] → 8.98% (-6.93%) [Q1 2024]

13% less funds holding

Funds holding: 70 [Q4 2023] → 61 (-9) [Q1 2024]

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

36% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 25

56% less capital invested

Capital invested by funds: $12.3M [Q4 2023] → $5.45M (-$6.87M) [Q1 2024]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$2

219%

upside

Avg. target

$4

538%

upside

High target

$6

857%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

BTIG Mark Massaro	219%upside $2	Buy Maintained	16 May 2024
Scotiabank Sung Ji Nam	857%upside $6	Sector Outperform Maintained	7 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about BNGO published over the past 30 days

Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants

Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Scientific Presentations Highlight OGM's Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) will be featured in three scientific presentations at the 2024 joint annual meeting for the American Society for Clinical Laboratory Science (ASCLS), the Association of Genetic Technologists (AGT), and the Society of American Federal Medical Laboratory Scientists (SAFMLS). The conference, which brings together laboratory professionals and industry partners affiliated with three professional societies for networking and educational sessions focused on chemistry, microbiology, hematology, molecular diagnostics and cytogenetics, will be held July 8-12, 2024, in Pittsburgh, Pennsylvania and online.

Scientific Presentations Highlight OGM's Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE: RVTY) under which Revvity will market and commercialize Bionano's VIA™ software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity's sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow's interpretation capabilities.

Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research

Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis

American Medical Association issues Category I CPT code for the use of optical genome mapping in genome-wide analysis related to hematological malignancies

Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis

3 Sorry Healthcare Stocks to Sell in May While You Still Can

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth.

3 Sorry Healthcare Stocks to Sell in May While You Still Can

Lab Instrument Industry Update - New Commercial Entrants

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

The 3 Best Healthcare Stocks to Buy in May 2024

Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular.

The 3 Best Healthcare Stocks to Buy in May 2024

Bionano Genomics, Inc. (BNGO) Q1 2024 Earnings Call Transcript

Start Time: 16:30 January 1, 0000 4:27 PM ET Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2024 Earnings Conference Call May 08, 2024, 16:30 PM ET Company Participants Erik Holmlin - President and CEO Gülsen Kama - CFO David Holmes - IR Conference Call Participants Sung Ji Nam - Scotiabank Operator Good day, and welcome to the Bionano First Quarter 2024 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) Q1 2024 Earnings Call Transcript

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2024.

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

See News Rankings